Lourdes Mozo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lourdes Mozo has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Jesús Gómez
Department of Immunology, Hospital Universitario Central de Asturias, Celestino Villamil S/N, 33006 Oviedo, Spain
4 shared publicationsAurora Menéndez
Department of Immunology, Hospital Universitario Central de Asturias, Celestino Villamil S/N, 33006 Oviedo, Spain
2 shared publicationsCarmen Gutiérrez
Department of Immunology Hospital Universitario Central de Asturias Oviedo Spain
2 shared publicationsEsther Escanlar
Departments of Immunology, Hospital Universitario Central de Asturias, Oviedo, Spain
2 shared publicationsLuis Caminal-Montero
Department of Internal Medicine, Hospital Universitario Central de Asturias, Celestino Villamil S/N, 33006 Oviedo, Spain
2 shared publicationsA Suárez
Department of Functional Biology, Immunology Area, Universidad de Oviedo, Oviedo, Spain
1 shared publication
Latest Publications
- 8 August 2014
- Published by SAGE Publications in Lupus
- Vol. 23 (14) , 1477-1485
Anti-ribosomal P antibodies are associated with elevated circulating IFNα and IL-10 levels in systemic lupus erythematosus patients
The objective of this paper is to analyze the relationship of anti-protein ribosomal P (RibP) antibodies with circulating levels of IFNα, TNFα, IFNγ, IL-17 and IL-10 in SLE. Disease activity and other systemic lupus erythematosus (SLE) features were also analyzed. Anti-RibP and other SLE-related antinuclear antibodies (ANA) were determined by fluoro-enzyme immunoassay in the sera of 107 SLE patients. Circulating cytokines were quantified by flow cytometry (IFNα, IL-10 and IL-17) or ELISA (TNFα and IFNγ). Anti-RibP-positive patients (14.9%) displayed significantly higher serum levels of IFNα (p = 0.023) and IL-10 (p = 0.016) than their negative counterparts. This cytokine upregulation was independent of the presence of other ANA even though, in our patient cohort, anti-dsDNA was found to be associated with anti-RibP (OR, CI 95%: 6.03, 1.32–27.93, p = 0.021) and to correlate with IL-10 levels (r = 0.204, p = 0.036). In fact, patients positive for anti-RibP but negative for anti-dsDNA exhibited the highest amounts of both IL-10 and IFN-α that were not related to disease activity since these patients showed lower SLEDAI than patients also positive for anti-dsDNA (p = 0.018). Anti-RibP positivity was also associated with early diagnosis, hypocomplementemia and leukopenia. Presence of anti-RibP was found to be related to increased serum IFNα and IL-10 levels independently of both antibody status and disease activity.
- 8 August 2014
- Published by SAGE Publications in Lupus
- Vol. 23 (14) , 1477-1485
Anti-ribosomal P antibodies are associated with elevated circulating IFNα and IL-10 levels in systemic lupus erythematosus patients
The objective of this paper is to analyze the relationship of anti-protein ribosomal P (RibP) antibodies with circulating levels of IFNα, TNFα, IFNγ, IL-17 and IL-10 in SLE. Disease activity and other systemic lupus erythematosus (SLE) features were also analyzed. Anti-RibP and other SLE-related antinuclear antibodies (ANA) were determined by fluoro-enzyme immunoassay in the sera of 107 SLE patients. Circulating cytokines were quantified by flow cytometry (IFNα, IL-10 and IL-17) or ELISA (TNFα and IFNγ). Anti-RibP-positive patients (14.9%) displayed significantly higher serum levels of IFNα (p = 0.023) and IL-10 (p = 0.016) than their negative counterparts. This cytokine upregulation was independent of the presence of other ANA even though, in our patient cohort, anti-dsDNA was found to be associated with anti-RibP (OR, CI 95%: 6.03, 1.32–27.93, p = 0.021) and to correlate with IL-10 levels (r = 0.204, p = 0.036). In fact, patients positive for anti-RibP but negative for anti-dsDNA exhibited the highest amounts of both IL-10 and IFN-α that were not related to disease activity since these patients showed lower SLEDAI than patients also positive for anti-dsDNA (p = 0.018). Anti-RibP positivity was also associated with early diagnosis, hypocomplementemia and leukopenia. Presence of anti-RibP was found to be related to increased serum IFNα and IL-10 levels independently of both antibody status and disease activity.
- Open Access
- 25 February 2014
- Published by Springer Nature in BMC Medicine
- Vol. 12 (1) , 1-8
Autoantibodies against MHC class I polypeptide-related sequence A are associated with increased risk of concomitant autoimmune diseases in celiac patients
Overexpression of autologous proteins can lead to the formation of autoantibodies and autoimmune diseases. MHC class I polypeptide-related sequence A (MICA) is highly expressed in the enterocytes of patients with celiac disease, which arises in response to gluten. The aim of this study was to investigate anti-MICA antibody formation in patients with celiac disease and its association with other autoimmune processes. We tested serum samples from 383 patients with celiac disease, obtained before they took up a gluten-free diet, 428 patients with diverse autoimmune diseases, and 200 controls for anti-MICA antibodies. All samples were also tested for anti-endomysium and anti-transglutaminase antibodies. Antibodies against MICA were detected in samples from 41.7% of patients with celiac disease but in only 3.5% of those from controls (P P P P <0.0001; odds ratio = 6.11). The risk was even higher when we also controlled for age (odds ratio = 11.69). Finally, we found that the associated risk of developing additional autoimmune diseases was 16 and 10 times as high in pediatric patients and adults with anti-MICA, respectively, as in those without. The development of anti-MICA antibodies could be related to a gluten-containing diet, and seems to be involved in the development of autoimmune diseases in patients with celiac disease, especially younger ones.
- 25 February 2014
- Published by Springer Nature in BMC Medicine
- Vol. 12 (1) , 1-8
Open AccessAutoantibodies against MHC class I polypeptide-related sequence A are associated with increased risk of concomitant autoimmune diseases in celiac patients
Overexpression of autologous proteins can lead to the formation of autoantibodies and autoimmune diseases. MHC class I polypeptide-related sequence A (MICA) is highly expressed in the enterocytes of patients with celiac disease, which arises in response to gluten. The aim of this study was to investigate anti-MICA antibody formation in patients with celiac disease and its association with other autoimmune processes. We tested serum samples from 383 patients with celiac disease, obtained before they took up a gluten-free diet, 428 patients with diverse autoimmune diseases, and 200 controls for anti-MICA antibodies. All samples were also tested for anti-endomysium and anti-transglutaminase antibodies. Antibodies against MICA were detected in samples from 41.7% of patients with celiac disease but in only 3.5% of those from controls (P P P P <0.0001; odds ratio = 6.11). The risk was even higher when we also controlled for age (odds ratio = 11.69). Finally, we found that the associated risk of developing additional autoimmune diseases was 16 and 10 times as high in pediatric patients and adults with anti-MICA, respectively, as in those without. The development of anti-MICA antibodies could be related to a gluten-containing diet, and seems to be involved in the development of autoimmune diseases in patients with celiac disease, especially younger ones.
- Open Access
- 1 January 2013
- Published by Wiley in The Scientific World Journal
- Vol. 2013 (1) , 832789
Common and Specific Associations of Anti‐SSA/Ro60 and Anti‐Ro52/TRIM21 Antibodies in Systemic Lupus Erythematosus
Little information exists about the association of anti‐SSA/Ro60 and anti‐Ro52/TRIM21 with systemic lupus erytematosus (SLE) features. In this work, we analysed the associations of both anti‐Ro reactivities with clinical and immunological manifestations in 141 SLE patients. Photosensitivity and xerophtalmia/xerostomia were found to be positively associated with both anti‐SSA/Ro60 (P = 0.024 and P = 0.019, resp.) and anti‐Ro52/TRIM21 (P = 0.026 and P = 0.022, resp.). In contrast, a negative association was detected regarding anti‐phospholipid antibodies, anti‐SSA/Ro60 having a stronger effect (P = 0.014) than anti‐Ro52/TRIM21. Anti‐SSA/Ro60 showed a specific positive association with hypocomplementemia (P = 0.041), mainly with low C4 levels (P = 0.008), whereas anti‐Ro52/TRIM21 was found to be positively associated with Raynaud’s phenomenon (P = 0.026) and cytopenia (P = 0.048) and negatively associated with anti‐dsDNA (P = 0.013). Lymphocytes are involved in the relationship between anti‐Ro52/TRIM21 and cytopenia since positive patients showed lower cell levels than negative patients (P = 0.036). In conclusion, anti‐SSA/Ro60 and anti‐Ro52/TRIM21 showed both common and specific associations in SLE. These data thus increase evidence of the different associations of the two anti‐Ro specificities even in a particular disease.
- 1 January 2013
- Published by Wiley in The Scientific World Journal
- Vol. 2013 (1) , 832789
Open AccessCommon and Specific Associations of Anti‐SSA/Ro60 and Anti‐Ro52/TRIM21 Antibodies in Systemic Lupus Erythematosus
Little information exists about the association of anti‐SSA/Ro60 and anti‐Ro52/TRIM21 with systemic lupus erytematosus (SLE) features. In this work, we analysed the associations of both anti‐Ro reactivities with clinical and immunological manifestations in 141 SLE patients. Photosensitivity and xerophtalmia/xerostomia were found to be positively associated with both anti‐SSA/Ro60 (P = 0.024 and P = 0.019, resp.) and anti‐Ro52/TRIM21 (P = 0.026 and P = 0.022, resp.). In contrast, a negative association was detected regarding anti‐phospholipid antibodies, anti‐SSA/Ro60 having a stronger effect (P = 0.014) than anti‐Ro52/TRIM21. Anti‐SSA/Ro60 showed a specific positive association with hypocomplementemia (P = 0.041), mainly with low C4 levels (P = 0.008), whereas anti‐Ro52/TRIM21 was found to be positively associated with Raynaud’s phenomenon (P = 0.026) and cytopenia (P = 0.048) and negatively associated with anti‐dsDNA (P = 0.013). Lymphocytes are involved in the relationship between anti‐Ro52/TRIM21 and cytopenia since positive patients showed lower cell levels than negative patients (P = 0.036). In conclusion, anti‐SSA/Ro60 and anti‐Ro52/TRIM21 showed both common and specific associations in SLE. These data thus increase evidence of the different associations of the two anti‐Ro specificities even in a particular disease.
- 17 September 2012
- Published by Taylor & Francis in Autoimmunity
- Vol. 46 (1) , 32-39
Clinical associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies: Diagnostic utility of their separate detection
Clinical associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies are not yet fully established. In order to analyse the diagnostic utility of their separate detection, we retrospectively revised the clinical data of 200 anti-SSA/Ro60 and/or anti-Ro52/TRIM21 positive patients identified by line immunoassay during ANA routine detection. Anti-SSA/Ro60 positive patients showed a significantly higher prevalence of autoimmune diseases (AIDs) independently on the presence of anti-Ro52/TRIM21 (OR 3.13, 95% CI 1.10–8.88, p = 0.032). Anti-SSA/Ro60 was independently associated with systemic lupus erythematosus (SLE) when comparing with Sjögren's syndrome (SS) and other systemic AIDs (OR 3.46, 95% CI 1.08–11.06, p = 0.036). The more frequent specificity found in cutaneous lupus erythematosus (CLE) was also anti-SSA/Ro60. In contrast, detection of isolated anti-Ro52/TRIM21 was characteristic of SS (7/35, 20.0%), diffuse cutaneous systemic sclerosis (dcSSc) (3/4, 75.0%), primary biliary cirrhosis (PBC) (4/5, 80.0%) and, specially, of polymyositis/dermatomyositis (PM/DM) (6/6, 100%). In fact, anti-Ro52/TRIM21 was the only antibody detected in 4 out of the 6 PM/DM patients. Malignancies mainly account for the observed high prevalence of mono-specific anti-Ro52/TRIM21 in patients with non-AIDs (10/15, 62.5%). In conclusion, this retrospective study supports the routine distinction of anti-SSA/Ro60 and anti-Ro52/TRIM21 due to their different clinical associations.
- 17 September 2012
- Published by Taylor & Francis in Autoimmunity
- Vol. 46 (1) , 32-39
Clinical associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies: Diagnostic utility of their separate detection
Clinical associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies are not yet fully established. In order to analyse the diagnostic utility of their separate detection, we retrospectively revised the clinical data of 200 anti-SSA/Ro60 and/or anti-Ro52/TRIM21 positive patients identified by line immunoassay during ANA routine detection. Anti-SSA/Ro60 positive patients showed a significantly higher prevalence of autoimmune diseases (AIDs) independently on the presence of anti-Ro52/TRIM21 (OR 3.13, 95% CI 1.10–8.88, p = 0.032). Anti-SSA/Ro60 was independently associated with systemic lupus erythematosus (SLE) when comparing with Sjögren's syndrome (SS) and other systemic AIDs (OR 3.46, 95% CI 1.08–11.06, p = 0.036). The more frequent specificity found in cutaneous lupus erythematosus (CLE) was also anti-SSA/Ro60. In contrast, detection of isolated anti-Ro52/TRIM21 was characteristic of SS (7/35, 20.0%), diffuse cutaneous systemic sclerosis (dcSSc) (3/4, 75.0%), primary biliary cirrhosis (PBC) (4/5, 80.0%) and, specially, of polymyositis/dermatomyositis (PM/DM) (6/6, 100%). In fact, anti-Ro52/TRIM21 was the only antibody detected in 4 out of the 6 PM/DM patients. Malignancies mainly account for the observed high prevalence of mono-specific anti-Ro52/TRIM21 in patients with non-AIDs (10/15, 62.5%). In conclusion, this retrospective study supports the routine distinction of anti-SSA/Ro60 and anti-Ro52/TRIM21 due to their different clinical associations.
- 1 July 2012
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 55 (1) , 50-55
Diagnostic Value of Anti‐deamidated Gliadin Peptide IgG Antibodies for Celiac Disease in Children and IgA‐deficient Patients
Objectives: The aim of the study was to analyze the diagnostic performance of anti‐deamidated gliadin peptide (dGp) immunoglobulin (Ig) G and IgA regarding the age at celiac disease (CD) diagnosis and the anti‐dGp IgG usefulness for diagnosing CD IgA‐deficient patients.Methods: Anti‐dGp IgG and IgA and anti‐native gliadin (nGlia) IgA were determined by enzyme fluoroimmunoassay in 100 newly diagnosed anti‐tissue transglutaminase (tTG) IgA‐positive pediatric and adult patients with CD and in 100 age‐matched patients with other digestive pathologies. Anti‐dGp IgG was evaluated in 6 CD IgA‐deficient patients.Results: When analyzing all of the patients, the anti‐dGp IgG assay showed higher diagnostic accuracy (area under receiver operating characteristic curve), specificity, and positive predictive value than anti‐dGp IgA and anti‐nGlia IgA. All of the diagnostic parameters corresponding to anti‐dGp IgG reached the same values as anti‐tTG IgA in children 7 years or younger. In older patients, both anti‐dGp isotypes showed an inverse behavior, IgG having a higher specificity and positive predictive value but a lower sensitivity and negative predictive value than IgA. Anti‐dGp levels were associated with the severity of intestinal lesions, and an inverse association was found regarding age at diagnosis. Both anti‐dGp IgG and IgA were found to be positive in the 9 patients with minimal intestinal changes included in the study. All of the patients with CD with IgA deficiency were positive for anti‐dGp IgG.Conclusions: The diagnostic performance of anti‐dGp depends on the antibody isotype and on the age at CD diagnosis, anti‐dGp IgG being a serological marker at least as useful as anti‐tTG IgA for detecting CD in children ages 7 years or younger. Our data also indicate that anti‐dGp IgG can improve the diagnosis of IgA‐deficient patients.
- 1 July 2012
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 55 (1) , 50-55
Diagnostic Value of Anti‐deamidated Gliadin Peptide IgG Antibodies for Celiac Disease in Children and IgA‐deficient Patients
Objectives: The aim of the study was to analyze the diagnostic performance of anti‐deamidated gliadin peptide (dGp) immunoglobulin (Ig) G and IgA regarding the age at celiac disease (CD) diagnosis and the anti‐dGp IgG usefulness for diagnosing CD IgA‐deficient patients.Methods: Anti‐dGp IgG and IgA and anti‐native gliadin (nGlia) IgA were determined by enzyme fluoroimmunoassay in 100 newly diagnosed anti‐tissue transglutaminase (tTG) IgA‐positive pediatric and adult patients with CD and in 100 age‐matched patients with other digestive pathologies. Anti‐dGp IgG was evaluated in 6 CD IgA‐deficient patients.Results: When analyzing all of the patients, the anti‐dGp IgG assay showed higher diagnostic accuracy (area under receiver operating characteristic curve), specificity, and positive predictive value than anti‐dGp IgA and anti‐nGlia IgA. All of the diagnostic parameters corresponding to anti‐dGp IgG reached the same values as anti‐tTG IgA in children 7 years or younger. In older patients, both anti‐dGp isotypes showed an inverse behavior, IgG having a higher specificity and positive predictive value but a lower sensitivity and negative predictive value than IgA. Anti‐dGp levels were associated with the severity of intestinal lesions, and an inverse association was found regarding age at diagnosis. Both anti‐dGp IgG and IgA were found to be positive in the 9 patients with minimal intestinal changes included in the study. All of the patients with CD with IgA deficiency were positive for anti‐dGp IgG.Conclusions: The diagnostic performance of anti‐dGp depends on the antibody isotype and on the age at CD diagnosis, anti‐dGp IgG being a serological marker at least as useful as anti‐tTG IgA for detecting CD in children ages 7 years or younger. Our data also indicate that anti‐dGp IgG can improve the diagnosis of IgA‐deficient patients.
- 15 February 2010
- Published by SAGE Publications in Lupus
- Vol. 19 (8) , 1002-1003
A case of polymyositis associated with the presence of anti-proliferating cell nuclear antigen antibodies, a marker typically considered SLE specific
- 15 February 2010
- Published by SAGE Publications in Lupus
- Vol. 19 (8) , 1002-1003
A case of polymyositis associated with the presence of anti-proliferating cell nuclear antigen antibodies, a marker typically considered SLE specific
- 1 February 2008
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 28 (4) , 285-290
Antibodies to Mitotic Spindle Apparatus: Clinical Significance of NuMA and HsEg5 Autoantibodies
The clinical associations of NuMA and HsEg5 antibodies, the main anti-mitotic spindle apparatus autoantibodies, remain unclear due to their extremely low prevalence.
- 1 February 2008
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 28 (4) , 285-290
Antibodies to Mitotic Spindle Apparatus: Clinical Significance of NuMA and HsEg5 Autoantibodies
The clinical associations of NuMA and HsEg5 antibodies, the main anti-mitotic spindle apparatus autoantibodies, remain unclear due to their extremely low prevalence.
- Open Access
- 13 February 2006
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 8 (2) , R42
Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs
Antimalarial agents have been widely used as disease-modifying antirheumatic drugs in the treatment of systemic lupus erythematosus (SLE) and other rheumatological diseases, although their mechanism of action has not yet been fully defined. It is known, however, that effective response to treatment is variable among patients. Thus, the identification of genetic predictors of treatment response would provide valuable information for therapeutic intervention. The aim of the present study was to analyze the effect of antimalarial treatment on tumor necrosis factor (TNF)α serum levels and evaluate the possible influence of TNFα and IL-10 functional genetic polymorphisms on the response to antimalarial drugs. To this end, TNFα serum levels were quantified in 171 SLE patients and 215 healthy controls by ELISA techniques and polymorphisms at positions -1,082 and -308 of the IL-10 and TNFα gene promoterswere determined by PCR amplification followed by hybridization with fluorescent-labeled allele-specific probes in 192 SLE patients and 343 matched controls. Data were related to clinical features and treatment at the time of sampling and during the course of the disease. Results showed a significantly higher amount of serum TNFα in the entire SLE population compared with controls. However, TNFα serum levels correlated negatively with the use of antimalarial treatment during at least three months before sampling. Patients under single or combined treatment with these drugs had TNFα serum levels similar to healthy controls, whereas untreated patients and those under corticosteroid or immunosuppressive therapies had increased amounts of this cytokine. This suggests, however, that antimalarial-mediated inhibition of TNFα was only significant in patients who were genetically high TNFα or low IL-10 producers. In addition, evaluation of SLE patients administered antimalarial drugs for three or more years who did not require any other specific SLE treatment indicates that patients with the combined genotype low IL-10/high TNFα are the best responders to antimalarial therapy, developing mild disease with a good course under this treatment. In conclusion, we proposed that an antimalarial-mediated downregulation of TNFα levels in SLE patients is influenced by polymorphisms at IL-10 and TNFα promoters. Our results may thus find important clinical application through the identification of patients who are the most likely to benefit from antimalarial therapy.
- 13 February 2006
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 8 (2) , R42
Open AccessCytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs
Antimalarial agents have been widely used as disease-modifying antirheumatic drugs in the treatment of systemic lupus erythematosus (SLE) and other rheumatological diseases, although their mechanism of action has not yet been fully defined. It is known, however, that effective response to treatment is variable among patients. Thus, the identification of genetic predictors of treatment response would provide valuable information for therapeutic intervention. The aim of the present study was to analyze the effect of antimalarial treatment on tumor necrosis factor (TNF)α serum levels and evaluate the possible influence of TNFα and IL-10 functional genetic polymorphisms on the response to antimalarial drugs. To this end, TNFα serum levels were quantified in 171 SLE patients and 215 healthy controls by ELISA techniques and polymorphisms at positions -1,082 and -308 of the IL-10 and TNFα gene promoterswere determined by PCR amplification followed by hybridization with fluorescent-labeled allele-specific probes in 192 SLE patients and 343 matched controls. Data were related to clinical features and treatment at the time of sampling and during the course of the disease. Results showed a significantly higher amount of serum TNFα in the entire SLE population compared with controls. However, TNFα serum levels correlated negatively with the use of antimalarial treatment during at least three months before sampling. Patients under single or combined treatment with these drugs had TNFα serum levels similar to healthy controls, whereas untreated patients and those under corticosteroid or immunosuppressive therapies had increased amounts of this cytokine. This suggests, however, that antimalarial-mediated inhibition of TNFα was only significant in patients who were genetically high TNFα or low IL-10 producers. In addition, evaluation of SLE patients administered antimalarial drugs for three or more years who did not require any other specific SLE treatment indicates that patients with the combined genotype low IL-10/high TNFα are the best responders to antimalarial therapy, developing mild disease with a good course under this treatment. In conclusion, we proposed that an antimalarial-mediated downregulation of TNFα levels in SLE patients is influenced by polymorphisms at IL-10 and TNFα promoters. Our results may thus find important clinical application through the identification of patients who are the most likely to benefit from antimalarial therapy.